^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | carfilzomib (Proteasome inhibitor) + pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Therapy for Previously Treated Multiple Myeloma:...The following regimens have been added for Bortezomib-Inhibitor Refractory, and Lenalidomide Refractory:...Carfilzomib/pomalidomide/dexamethasone...
Secondary therapy:
dexamethasone
